274 related articles for article (PubMed ID: 28608116)
21. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer.
Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
Gastric Cancer; 2013 Apr; 16(2):133-9. PubMed ID: 22527186
[TBL] [Abstract][Full Text] [Related]
22. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer.
Mori M; Shuto K; Kosugi C; Narushima K; Hayashi H; Matsubara H; Koda K
BMC Cancer; 2018 Dec; 18(1):1261. PubMed ID: 30558575
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
[TBL] [Abstract][Full Text] [Related]
24. Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery.
Okuyama T; Korenaga D; Edagawa A; Itoh S; Oki E; Kawanaka H; Ikeda Y; Kakeji Y; Tateishi M; Tsujitani S; Takenaka K; Maehara Y
Surg Today; 2012 Aug; 42(8):734-40. PubMed ID: 22278622
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Long-Term Efficacy in S-1 and Capecitabine With Oxaliplatin as Adjuvant Chemotherapy for Patients With Gastric Cancer After Curative Surgery: A Retrospective, Single-Center Observational Study.
Oh SE; An JY; Choi MG; Lee JH; Sohn TS; Bae JM
Technol Cancer Res Treat; 2021; 20():15330338211039679. PubMed ID: 34605706
[No Abstract] [Full Text] [Related]
26. [Prognosis and clinical course of gastric cancer with para-aortic lymph node metastasis after curative D2 gastrectomy and adjuvant chemotherapy with S-1].
Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A; Rino Y; Masuda M
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2331-3. PubMed ID: 22202372
[TBL] [Abstract][Full Text] [Related]
27. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Ito S; Ohashi Y; Sasako M
BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
[TBL] [Abstract][Full Text] [Related]
28. Safety and feasibility of S-1 adjuvant chemotherapy for gastric cancer in elderly patients.
Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
Gastric Cancer; 2012 Jan; 15(1):76-82. PubMed ID: 21717091
[TBL] [Abstract][Full Text] [Related]
29. [Clinical significance of the human epidermal growth factor receptor 2( HER2) in patients with recurrent gastric cancer who received S-1 adjuvant chemotherapy].
Aoyama T; Hayashi T; Fujikawa H; Ogata T; Cho H; Wada H; Kitani Y; Yukawa N; Oshima T; Rino Y; Ozawa Y; Masuda M; Yoshikawa T
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1647-9. PubMed ID: 24393876
[TBL] [Abstract][Full Text] [Related]
30. [Examination of continuity of S-1 adjuvant chemotherapy for gastric cancer patients after gastrectomy].
Kawabata R; Imamura H; Kishimoto T; Anami S; Yasui Y; Fujino M; Fujii C; Sumida R; Furukawa H
Gan To Kagaku Ryoho; 2011 May; 38(5):793-5. PubMed ID: 21566439
[TBL] [Abstract][Full Text] [Related]
31. Prediction of S-1 adjuvant chemotherapy benefit in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis.
Nakamura K; Hatakeyama K; Furukawa K; Fujiya K; Kamiya S; Hikage M; Tanizawa Y; Bando E; Ohshima K; Urakami K; Machida N; Yasui H; Yamaguchi K; Terashima M
Gastric Cancer; 2020 Jul; 23(4):648-658. PubMed ID: 32185558
[TBL] [Abstract][Full Text] [Related]
32. Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer.
Ichikawa W; Terashima M; Ochiai A; Kitada K; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M
Gastric Cancer; 2017 Mar; 20(2):263-273. PubMed ID: 26884344
[TBL] [Abstract][Full Text] [Related]
33. Late start and insufficient S-1 dose in adjuvant chemotherapy can lead to poor prognosis in stage II/III gastric cancer.
Miyatani K; Saito H; Shimizu S; Kono Y; Murakami Y; Shishido Y; Matsunaga T; Fukumoto Y; Fujiwara Y
Int J Clin Oncol; 2019 Oct; 24(10):1190-1196. PubMed ID: 31104175
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience.
Yen HH; Chen CN; Yeh CC; Lai IR
World J Surg Oncol; 2021 Apr; 19(1):124. PubMed ID: 33865416
[TBL] [Abstract][Full Text] [Related]
35. Clinical Relevance of Postoperative Neutrophil-Lymphocyte Ratio (NLR) to Recurrence After Adjuvant Chemotherapy of S-1 for Gastric Cancer.
Tanaka H; Tamura T; Toyokawa T; Muguruma K; Miki Y; Kubo N; Sakurai K; Hirakawa K; Ohira M
Anticancer Res; 2018 Jun; 38(6):3745-3751. PubMed ID: 29848737
[TBL] [Abstract][Full Text] [Related]
36. [Alternate-day oral therapy with S-1 for adjuvant chemotherapy of gastric cancer].
Takebayashi K; Kawai Y; Tagi T; Matsumura M; Shimizu K; Yamamoto H; Mekata E; Tani T; Sato M
Gan To Kagaku Ryoho; 2012 Mar; 39(3):385-7. PubMed ID: 22421764
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T
Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800
[TBL] [Abstract][Full Text] [Related]
38. Tumor size ≥50 mm as an Independent Prognostic Factor for Patients with Stage II or III Gastric Cancer After Postoperative S-1 Monotherapy: Analysis of a Multi-institution Dataset.
Tsutsuyama M; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
World J Surg; 2020 Jan; 44(1):194-201. PubMed ID: 31552460
[TBL] [Abstract][Full Text] [Related]
39. [Prognostic factors and usefulness of chemotherapy with S-1 in patients received gastrectomy for stage IV gastric cancer].
Maehara N; Hidaka H; Nagaike K; Nakashima S; Hotokezaka M; Chijiiwa K
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1111-4. PubMed ID: 19620798
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study.
Kim IH; Park SS; Lee CM; Kim MC; Kwon IK; Min JS; Kim HI; Lee HH; Lee SI; Chae H
Ann Surg Oncol; 2018 May; 25(5):1176-1183. PubMed ID: 29450755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]